La maladie de Parkinson en France (serveur d'exploration) - Curation (Ncbi)

Index « Keywords » - entrée « Neuroprotective Agents (therapeutic use) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuropsychological Tests  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]
Ident.Authors (with country if any)Title
000222 (2001) S. Thobois [France] ; S. Guillouet ; E. BroussolleContributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
000223 (2002) Maria C. Obinu [France] ; Michel Reibaud ; Véronique Blanchard ; Saliha Moussaoui ; Assunta ImperatoNeuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
000268 (2002) Anne-Marie Bonnet [France][Alpha-2 adrenergic receptors and Parkinson's disease].
000289 (2003) Olivier Rascol [France] ; C. Brefel-Courbon ; P. Payoux ; J. FerreiraThe management of patients with early Parkinson's disease.
000290 (2003) Alim-Louis Benabid [France] ; Laurent Vercucil ; Abdelhamid Benazzouz ; Adnan Koudsie ; Stephan Chabardes ; Lorella Minotti ; Philippe Kahane ; Michèle Gentil ; Doris Lenartz ; Christian Andressen ; Paul Krack ; Pierre PollakDeep brain stimulation: what does it offer?
000346 (2003) Erwan Bezard [France]Neuroprotection for Parkinson's disease: a call for clinically driven experimental design.
000439 (2004) Wassilios Meissner [France] ; Michael P. Hill ; François Tison ; Christian E. Gross ; Erwan BezardNeuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.
000520 (2005) Stéphane Thobois [France] ; Florence Delamarre-Damier ; Pascal DerkinderenTreatment of motor dysfunction in Parkinson's disease: an overview.
000594 (2006) Erwan Bezard [France] ; Irene Gerlach ; Rosario Moratalla ; Christian E. Gross ; Reinhard Jork5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.
000646 (2006) Kathy Dujardin [France] ; David Devos ; Stéphane Duhem ; Alain Destée [France] ; Rose-Marie Marié ; Franck Durif ; Lucette Lacomblez ; Jacques Touchon ; Pierre Pollak ; Jean-Jacques PéréUtility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
000652 (2006) E C Hirsch [France]How to judge animal models of Parkinson's disease in terms of neuroprotection.
000683 (2006) Rasagiline. Parkinson's disease: a simple me-too.
000719 (2007) Laïla Amazzal [France] ; Agnès Lapôtre ; Frédéric Quignon ; Denyse BagrelMangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells.
000770 (2007) Pierre Etienne Chabrier [France] ; Michel AuguetPharmacological properties of BN82451: a novel multitargeting neuroprotective agent.
000773 (2008) Grégory Porras [France] ; Erwan BezardPreclinical development of gene therapy for Parkinson's disease.
000779 (2007) Soumya Rasouri [France] ; Marie Lagouge ; Johan Auwerx[SIRT1/PGC-1: a neuroprotective axis?].
000934 (2008) Gilbert Bensimon [France] ; Albert Ludolph [Allemagne] ; Yves Agid [France] ; Marie Vidailhet [France] ; Christine Payan [France] ; P. Nigel Leigh [Royaume-Uni]Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
000968 (2009) Olivier Rascol [France]"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
000982 (2009) Etienne C. Hirsch [France] ; Stéphane HunotNeuroinflammation in Parkinson's disease: a target for neuroprotection?
000A64 (2010) D. Devos [France] ; R. Bordet ; L. Defebvre[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
000D60 (2012) Mickael Decressac [France] ; Stéphanie Pain ; Pierre-Yves Chabeauti ; Laura Frangeul ; Nathalie Thiriet ; Herbert Herzog ; Jackie Vergote ; Sylvie Chalon ; Mohamed Jaber ; Afsaneh GaillardNeuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024